Studies over the past decade have shed light on how proteases activate the epithelial sodium channel (ENaC). Two ENaC subunits (a and g) have short stretches of embedded amino acid residues that inhibit the channel. Following proteasedependent cleavage of these subunits at sites flanking these inhibitory tracks, fragments are released and channels are activated.
Studies over the past decade have shed light on how proteases activate the epithelial sodium channel (ENaC). Two ENaC subunits (a and g) have short stretches of embedded amino acid residues that inhibit the channel. Following proteasedependent cleavage of these subunits at sites flanking these inhibitory tracks, fragments are released and channels are activated.
The serine protease furin is expressed in the trans-Golgi network and processes proteins transiting through the biosynthetic pathway. Furin cleaves the a subunit of ENaC twice at sites flanking an inhibitory track, transitioning channels from a low-to a moderate-activity state. Furin cleaves the g subunit once, preceding its inhibitory track. Subsequent cleavage by a second protease at a site distal to the g subunit inhibitory track releases another inhibitory track and transitions ENaC to a high activity state. 1,2 A population of channels that have bypassed proteolytic processing has been observed at the cell surface, adding a layer of complexity regarding channel regulation by proteases (for reviews, see Kashlan and Kleyman 3 and Kleyman et al. 4 ).
A growing number of proteases have been shown to cleave the g subunit at sites distal to the inhibitory track, including prostasin, transmembrane protease serine 4 (TMPRSS4), matriptase, kallikrein, plasmin, and elastase. While there is some evidence that kallikrein and prostasin may have a role in activating ENaC in the distal nephron or in other epithelia, 5, 6 the key proteases responsible for cleaving the g subunit at a site distal to the inhibitory track under specific pathophysiologic conditions have not been clearly defined. To complicate matters, proteases function in cascades (e.g., clotting factors). Differentiating upstream proteases from those that directly cleave and activate the channel under different states is challenging. In addition, it is likely that we have not identified all of the proteases that can cleave and activate ENaC.
Multiple lines of evidence suggest that ENaC processing and activation is a physiologically relevant phenomenon. In the context of extracellular volume depletion or aldosterone administration in the absence volume depletion, increases in channel expression at the cell surface and proteolytic processing of the a and g subunits have been described. 7, 8 Prostasin and/or kallikrein could have a role in cleaving the g subunit in these settings. In the setting of proteinuria, filtration of plasminogen by damaged glomeruli and its subsequent conversion to plasmin by tubular urokinase may activate ENaC, contributing to the renal sodium retention seen in this setting. 9, 10 Antibodies directed against the amino-or carboxyl-termini of ENaC subunits can readily differentiate cleaved from noncleaved ENaC subunits. 11 The challenge is demonstrating that a subunit has been cleaved twice, shedding an inhibitory track. 10, 12 In this issue of JASN, Zachar et al. address important questions regarding the proteolytic processing of the g subunit in human kidney. 13 Specifically, they examined whether g subunit processing in human kidney is affected by the administration of an angiotensin-converting enzyme inhibitor, angiotensin-receptor blocker, or a diuretic, and whether proteolytic processing is altered in the setting of nephrotic syndrome.
Two antibodies were used to answer these questions. One antibody, directed against the g subunit inhibitory track, was previously described by Svenningsen et al. 14 Zachar et al. generated a new antibody that is directed against residues immediately following the prostasin/kallikrein cleavage site. Surprisingly, this antibody appears to require cleavage at the prostasin/kallikrein site in order to recognize its epitope.
The authors asked whether individuals on diuretics exhibit altered g subunit expression or proteolytic cleavage. Increases in full-length and presumably furin-cleaved g subunits were noted in individuals on diuretics compared with controls. The ratio of furin-cleaved to full-length g subunit was unchanged, suggesting that diuretics did do not alter the extent of furin-dependent channel processing. Individuals receiving an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker had levels of expression of fulllength and presumably furin-cleaved g subunits that were similar to controls. Evidence of cleavage at the prostasin/ kallikrein site, corresponding to a channel-activating event, was noted in some individuals receiving these medications, while absent in controls. The increased g subunit expression in individuals receiving diuretics could reflect relative volume depletion. However, caveats in interpreting this work are that the reason these drugs were administered, and details regarding the extracellular volume status of these patients were not provided.
Individuals with proteinuria also had more full-length and presumably furin-cleaved g subunit. A decreased ratio of furin-cleaved to full-length g subunit was also noted, suggesting that a second processing event had occurred releasing the g subunit inhibitory track. Evidence of cleavage at the prostasin/ kallikrein site was noted in five of six individuals with proteinuria, providing additional support of a second processing event. It is interesting, but not surprising, that the two antibodies localized g subunits to different sites within principal cells in the distal nephron of kidneys from individuals with proteinuria. While the antibody directed against the inhibitory track showed somewhat diffuse intracellular staining, the antibody recognizing a putatively prostasin/kallikrein-cleaved g subunit showed punctate staining.
These results provide intriguing clues regarding g subunit processing in humans under different states. First, there is furin-dependent processing of the g subunit in the human kidney. Second, under certain conditions there appears to be cleavage at the prostasin/kallikrein site. This is particularly evident in individuals with proteinuria and provides an important clue regarding proteases that cleave the g subunit and activate the channel in proteinuric states. If plasmin, generated by filtered plasminogen, is primarily responsible for cleaving the g subunit in this setting, cleavage would occur following a lysine residue that is eight residues distal to the prostasin/kallikrein site. 9 The resulting fragment would be unlikely to be recognized by the new antibody used by the authors because it would contain only two of the residues in the antigen used to raise the antibody. A simple test could confirm that the antibody would not recognize a plasmincleaved fragment. Given the previous work of Svenningsen et al. showing that plasmin cleaves and activates prostasin, 14 the findings of Zachar et al. are consistent with prostasindependent cleavage of the g subunit in proteinuric states.
There are several caveats regarding these findings. First, the prostasin/kallikrein cleavage site consists of a track of four basic residues, and it is likely that other proteases are present in the lumen of the distal nephron and are capable of cleaving the channel at this site. Second, the size of the fragment identified with the new antibody (45 kD) is not consistent with a g subunit that is simply cleaved at the prostasin/kallikrein site. 1 The size of the fragment should be about 5 kD less than the furin cleaved fragment, or about 70 kD. Possible explanations for this discrepancy include additional cleavage at a site preceding the second transmembrane domain, as has been observed by others, 15 or that this 45-kD fragment is a cross-reacting polypeptide and not related to the g subunit. Immunolocalization with this antibody is consistent with the antibody recognizing ENaC. Coimmunoprecipitation studies with this antibody and an antibody directed against the carboxyl terminus of the g subunit could address the first possibility (the 45-kD fragment should not coimmunoprecipitate). Third, these findings do not exclude the possibility that a component of the g subunit in proteinuric states is cleaved by plasmin at the lysine residue mentioned above. The antibodies used by the authors would likely not detect a plasmin-cleaved fragment. Fourth, on the basis of previous work it is difficult to explain how the 37-kDa fragment recognized by the antibody against the inhibitory track was generated. This is not consistent with a single cleavage at or in close proximity to the prostasin/kallikrein site. 11 In summary, Zachar et al. have generated a novel antibody and presented new findings regarding human kidney g subunit processing in in the setting of proteinuria. Their work also raises new questions.
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Blockade of the renin-angiotensin system (RAS) is a universally accepted part of antihypertensive therapy in renal diseases and of therapies aiming to retard the progression of CKD. While this approach is undoubtedly effective, a considerable number of patients are still not being adequately treated and progress toward ESRD. One of the reasons for this progression are the many counter-regulatory mechanisms that come into play when single components of the RAS are blocked (such as upregulation of renin or so-called aldosterone breakthrough). In addition, the intrarenal RAS may still be activated when the systemic RAS is fully blocked; for example, renal tubular angiotensin II concentrations markedly exceed systemic concentrations. 1 Thus, more effective RAS blockade has long been investigated as a means of providing better renal protection in CKD.
In the present issue of JASN, Lili Zhou and colleagues address this issue. 2 They first performed a bioinformatics screen of the five RAS genes (angiotensinogen, renin, angiotensinconverting enzyme, and the two angiotensin II receptors), all of which were simultaneously upregulated in experimental proteinuric renal disease in the tubules. The screen yielded common promotor sequences in all five genes that can serve as binding sites for T cell factor/lymphoid enhancer factor (TCF/LEF). This observation laid the basis for investigating a potential link between Wnt/b-catenin and the RAS.
A few basics on the Wnt/b-catenin pathway: Wnt proteins are a family of secreted glycoproteins (about 20 exist in humans) that bind Frizzled receptors and induce three signaling pathways: the canonical pathway, the noncanonical planar cell polarity pathway, and the noncanonical Wnt/calcium pathway. Of these, it is the canonical Wnt pathway that causes the cytoplasmic accumulation of b-catenin by inhibiting b-catenin's "destruction" complex, in particular glycogen synthase kinase-3b. Inhibition of glycogen synthase kinase-3b results in the accumulation of nonphosphorylated b-catenin in the cytoplasm, which is not easily degraded and translocates into the nucleus. Here it assembles a protein complex together with the transcriptional coactivator cAMP response element-binding protein (CREB)-binding protein to then activate transcription factors belonging to the TCF/LEF family. b-Catenin also performs a radically different cellular function, namely cell-cell adhesion in adherens junctions, and thus is an example of so-called moonlighting. Through this second role, b-catenin is involved in maintaining epithelial cell barriers, including the cellular contact inhibition necessary to maintain a single cell epithelial layer.
The next logical step in the study of Zhou et al. was to block the b-catenin pathway with a small molecule (ICG-001) that disrupts its binding to CREB-binding protein. 2 ICG-001, described 10 years ago, is one of many small-molecule inhibitors of b-catenin/TCF-mediated transcription, and it downregulates the expression of a subset of b-catenin/TCFresponsive genes. 3 This effectively abolished the induction of all components of the activated RAS in the authors' murine model of renal disease (doxorubicin-induced nephropathy). 2 Of high clinical relevance, both transient and late treatment with ICG-001 restored podocyte function and repressed proteinuria, renal inflammation, and fibrosis. The latter is consistent with the findings of many studies that documented potent antifibrotic effects of canonical Wnt signaling blockade in the kidney, 4 lung, 5 skin, 6 and other organs. It also provides an exciting link between the RAS, TGF-b, and the Wnt/b-catenin pathway. In this scenario, RAS activation results in TGF-b activation, which is well documented in the kidney. 7 Recent data also demonstrate that TGF-b stimulates canonical Wnt signaling by decreasing the expression of the Wnt antagonist Dickkopf-1, highlighting how both pathways interact to mediate fibrotic diseases. 6 Together with TGF-b1, b-catenin also contributes to the epithelial cell phenotype switch known as
